Still on physicians’ attitude to medical marijuana

Authors

  • Olukayode Abayomi Department of Mental Health, Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso, Oyo State, Nigeria
  • Emmanuel Babalola Department of Clinical Services, Neuropsychiatric Hospital, Aro, Abeokuta, Ogun State, Nigeria

Keywords:

Medical marijuana

Abstract

Desai and Patel highlighted in a recent review that “there are several issues related to medical marijuana, which concern public health such as its medical use, harmful effects, laws and physicians role.” Certainly, physician’s perspectives and position on the relative harm and benefits of marijuana contribute to the growing controversy over its legalization in western countries. Interestingly, the seeming resistance of physicians in western countries to marijuana prescription appears to mirror the position of psychiatrists in developing countries. For instance, in a recent survey of psychiatrists in Nigeria, up to 55% of psychiatrists were against the medical use of marijuana.

References

Desai U, Patel P. Medical Maurijuan - A public health perspective. Int Basic Clin Pharmacol. 2013;2(2):136-43.

Babalola E, Otu E, Oluwaranti O, Abayomi O. Medical Marijuana: evil or Saint? Psychiatrists’ Attitude to Medical Use of Marijuana. Ogun NMA News Bulletin; 2014.

Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509-17.

Carabellese F, Candelli C, Martinelli D, La Tegola D, Catanesi R. Cannabis use and violent behaviour: a psychiatric patients cohort study in Southern Italy. Riv Psichiatr. 2013;48(1):43 50.

Hall W, Degenhardt L. Medical marijuana initiatives: are they justified? How successful are they likely to be? CNS Drugs. 2003;17(10):689-97.

Downloads

Published

2017-01-29

How to Cite

Abayomi, O., & Babalola, E. (2017). Still on physicians’ attitude to medical marijuana. International Journal of Basic & Clinical Pharmacology, 3(6), 1098–1098. Retrieved from https://www.ijbcp.com/index.php/ijbcp/article/view/1197

Issue

Section

Letter to the Editor